標(biāo)題: Titlebook: Chronic Leukemias and Lymphomas; Biology, Pathophysio Gary J. Schiller Book 2003 Springer Science+Business Media New York 2003 Staging.biol [打印本頁(yè)] 作者: protocol 時(shí)間: 2025-3-21 20:06
書目名稱Chronic Leukemias and Lymphomas影響因子(影響力)
書目名稱Chronic Leukemias and Lymphomas影響因子(影響力)學(xué)科排名
書目名稱Chronic Leukemias and Lymphomas網(wǎng)絡(luò)公開度
書目名稱Chronic Leukemias and Lymphomas網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Chronic Leukemias and Lymphomas被引頻次
書目名稱Chronic Leukemias and Lymphomas被引頻次學(xué)科排名
書目名稱Chronic Leukemias and Lymphomas年度引用
書目名稱Chronic Leukemias and Lymphomas年度引用學(xué)科排名
書目名稱Chronic Leukemias and Lymphomas讀者反饋
書目名稱Chronic Leukemias and Lymphomas讀者反饋學(xué)科排名
作者: nominal 時(shí)間: 2025-3-21 21:57
Book 2003es of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin‘s disease. In their integrated surveys of these chronic myeloproliferative a作者: 突襲 時(shí)間: 2025-3-22 03:53 作者: 神經(jīng) 時(shí)間: 2025-3-22 05:03 作者: 加花粗鄙人 時(shí)間: 2025-3-22 12:10 作者: Diuretic 時(shí)間: 2025-3-22 16:19
2364-1134 d cutaneous lymphomas. Special emphasis is given to the mechanisms of disease progression with authoritative insightsinto the promising new era of antineoplastic pharmacology.978-1-4684-9732-8978-1-59259-308-8Series ISSN 2364-1134 Series E-ISSN 2364-1142 作者: Diuretic 時(shí)間: 2025-3-22 18:17 作者: 異端 時(shí)間: 2025-3-22 21:40 作者: LEERY 時(shí)間: 2025-3-23 03:46
Myeloproliferative Syndromes,logenous leukemia (CML). Several other clinical entities may be considered myeloproliferative as well (Table 1). It may not be possible to definitively classify a chronic myeloid disorder as either MDS or CMPDs because of overlapping clinical and pathologic features.作者: cleaver 時(shí)間: 2025-3-23 05:35
Advances in the Biology and Treatment of Multiple Myeloma,as well. Newer bisphosphonates may offer greater ease of administration, improved efficacy, and possibly even enhanced anti-tumor effect. Finally, thalidomide and other new agents offer new therapeutic alternatives to myeloma patients who were previously refractory to multiple agents.作者: 鍵琴 時(shí)間: 2025-3-23 10:50
The UN Response to the Balkan Warstivity .. T-LGL likely represent in vivo-activated cytotoxic T-lymphocytes, which display non-major histocompatibility complex (MHC)-restricted cytotoxicity in vitro, and have clonal T-cell-receptor (TCR) gene rearrangements. NK-LGL also mediate non-MHC restricted cytotoxicity, but do not have TCR gene rearrangements.作者: Carcinogenesis 時(shí)間: 2025-3-23 16:45
How to Choose New Axioms for Set Theory?and refined treatment regimens, often tested in randomized controlled trials, result in a cure for more than 80% of newly diagnosed patients. Moreover, these improvements in treatment have been accompanied by reductions in the late effects of the therapy.作者: Diatribe 時(shí)間: 2025-3-23 18:37
Large Granular Lymphocyte Proliferative Diseases,tivity .. T-LGL likely represent in vivo-activated cytotoxic T-lymphocytes, which display non-major histocompatibility complex (MHC)-restricted cytotoxicity in vitro, and have clonal T-cell-receptor (TCR) gene rearrangements. NK-LGL also mediate non-MHC restricted cytotoxicity, but do not have TCR gene rearrangements.作者: 痛苦一下 時(shí)間: 2025-3-24 01:38
,Hodgkin’s Disease,and refined treatment regimens, often tested in randomized controlled trials, result in a cure for more than 80% of newly diagnosed patients. Moreover, these improvements in treatment have been accompanied by reductions in the late effects of the therapy.作者: Needlework 時(shí)間: 2025-3-24 04:10 作者: ARIA 時(shí)間: 2025-3-24 08:38
You Must Be Mad: UN Headquarters,linical features are the sequelae of bone marrow failure and the compressive syndromes that result from gross enlargement of lymphoid organs. In addition, CLL is associated with humoral and cell-mediated immunodeficiencies as well as a greatly enhanced risk of autoimmune cytopenias—particularly auto作者: ciliary-body 時(shí)間: 2025-3-24 11:47 作者: Macronutrients 時(shí)間: 2025-3-24 15:32
https://doi.org/10.1007/978-94-017-6025-6% of the cases are of B-cell phenotype. Definitional problems exist regarding specificity of diagnosis for these unusual leukemias. The recent World Health Organization (WHO) classification recognizes the existence of these entities and attempts to delineate specific diagnostic criteria.作者: inflame 時(shí)間: 2025-3-24 21:08 作者: laceration 時(shí)間: 2025-3-25 02:04
https://doi.org/10.1057/9781403980205 . wrote of a patient who presented with complaints of intense pruritus, who was found to have erythroderma, lymphadenopathy, and abnormal “monster” hyper-convoluted mononuclear cells circulating in the peripheral blood. Twenty-three years later, the Sézary syndrome was recognized in the American me作者: Glycogen 時(shí)間: 2025-3-25 05:08 作者: Transfusion 時(shí)間: 2025-3-25 10:17
Frances Pilch,Joseph Derdzinskiproliferative disorders. The myelodysplastic syndromes (MDS) are characterized by trilineage myeloid bone-marrow dysplasia with variable degrees of associated peripheral cytopenias. In contrast, the chronic myeloproliferative disorders (CMPDs) are characterized by the presence of varying degrees of 作者: addition 時(shí)間: 2025-3-25 12:23 作者: 變白 時(shí)間: 2025-3-25 16:54
Frances Pilch,Joseph Derdzinskihistory, and presumed incurability to conventional treatments when disseminated. This descriptive term was initially developed to describe the follicular small cleaved cell, the follicular mixed cell, and the small lymphocytic lymphoma of the Working Formulation (WF) ..作者: NAVEN 時(shí)間: 2025-3-25 20:16
https://doi.org/10.1007/978-3-030-15655-8pproximately 30%, 6%, and 2% of newly diagnosed non-Hodgkin’ s lymphomas, respectively .. Although they are clearly different diseases biologically, these illnesses share a number of clinical characteristics. The epidemiology, pathogenesis/biology, diagnosis, and treatment of these disorders is disc作者: 紡織品 時(shí)間: 2025-3-26 01:07
How to Choose New Axioms for Set Theory?56. Despite its relative rarity, Hodgkin’ s disease is one of the most intensively studied of all malignancies. These studies have led to a detailed understanding of the clinical and pathologic features of the disease and have rendered Hodgkin’ s disease one of the most curable cancers. It is now ge作者: catagen 時(shí)間: 2025-3-26 08:13 作者: blackout 時(shí)間: 2025-3-26 08:39
978-1-4684-9732-8Springer Science+Business Media New York 2003作者: 披肩 時(shí)間: 2025-3-26 15:47
Chronic Leukemias,150 years ago. In the following years, physicians have recognized the heterogeneous spectrum of leukemia. They also developed a fuller understanding of the clinical features, natural history, and morphology of leukemia. The classification of leukemia into its various subtypes became possible in the mid-twentieth century.作者: CLOT 時(shí)間: 2025-3-26 18:15 作者: CHOKE 時(shí)間: 2025-3-26 21:00
Hairy Cell Leukemia,he median age is 52 yr at presentation, with a 4:1 male predominance. The disease is rare in Asian or African Americans, and has a higher incidence in Ashkenazi Jews, and occasional familial cases have been described .,..作者: sperse 時(shí)間: 2025-3-27 03:28
Prolymphocytic Leukemias,% of the cases are of B-cell phenotype. Definitional problems exist regarding specificity of diagnosis for these unusual leukemias. The recent World Health Organization (WHO) classification recognizes the existence of these entities and attempts to delineate specific diagnostic criteria.作者: 頌揚(yáng)本人 時(shí)間: 2025-3-27 08:39
,Sézary Syndrome, . wrote of a patient who presented with complaints of intense pruritus, who was found to have erythroderma, lymphadenopathy, and abnormal “monster” hyper-convoluted mononuclear cells circulating in the peripheral blood. Twenty-three years later, the Sézary syndrome was recognized in the American medical literature by Taswell and Winkelmann ..作者: 高興去去 時(shí)間: 2025-3-27 12:56 作者: 在前面 時(shí)間: 2025-3-27 16:24
Aggressive Large-Cell Lymphomas,pproximately 30%, 6%, and 2% of newly diagnosed non-Hodgkin’ s lymphomas, respectively .. Although they are clearly different diseases biologically, these illnesses share a number of clinical characteristics. The epidemiology, pathogenesis/biology, diagnosis, and treatment of these disorders is discussed in this chapter.作者: 使長(zhǎng)胖 時(shí)間: 2025-3-27 20:07
Gary J. SchillerIncludes supplementary material: 作者: 使長(zhǎng)胖 時(shí)間: 2025-3-28 01:15
Current Clinical Oncologyhttp://image.papertrans.cn/c/image/226387.jpg作者: 多產(chǎn)子 時(shí)間: 2025-3-28 02:47 作者: Malaise 時(shí)間: 2025-3-28 08:42
Reflections on a United Nations‘ Career150 years ago. In the following years, physicians have recognized the heterogeneous spectrum of leukemia. They also developed a fuller understanding of the clinical features, natural history, and morphology of leukemia. The classification of leukemia into its various subtypes became possible in the mid-twentieth century.作者: 詞匯記憶方法 時(shí)間: 2025-3-28 14:19
You Must Be Mad: UN Headquarters,linical features are the sequelae of bone marrow failure and the compressive syndromes that result from gross enlargement of lymphoid organs. In addition, CLL is associated with humoral and cell-mediated immunodeficiencies as well as a greatly enhanced risk of autoimmune cytopenias—particularly autoimmune hemolytic anemia (AIHA).作者: CARE 時(shí)間: 2025-3-28 15:24
Reflections on a United Nations‘ Careerhe median age is 52 yr at presentation, with a 4:1 male predominance. The disease is rare in Asian or African Americans, and has a higher incidence in Ashkenazi Jews, and occasional familial cases have been described .,..作者: 試驗(yàn) 時(shí)間: 2025-3-28 21:20 作者: 使長(zhǎng)胖 時(shí)間: 2025-3-28 22:54 作者: congenial 時(shí)間: 2025-3-29 03:37 作者: 額外的事 時(shí)間: 2025-3-29 10:31
https://doi.org/10.1007/978-3-030-15655-8pproximately 30%, 6%, and 2% of newly diagnosed non-Hodgkin’ s lymphomas, respectively .. Although they are clearly different diseases biologically, these illnesses share a number of clinical characteristics. The epidemiology, pathogenesis/biology, diagnosis, and treatment of these disorders is discussed in this chapter.作者: 閃光你我 時(shí)間: 2025-3-29 13:23 作者: 發(fā)電機(jī) 時(shí)間: 2025-3-29 18:56 作者: needle 時(shí)間: 2025-3-29 22:03 作者: LAY 時(shí)間: 2025-3-30 03:04
Prolymphocytic Leukemias,% of the cases are of B-cell phenotype. Definitional problems exist regarding specificity of diagnosis for these unusual leukemias. The recent World Health Organization (WHO) classification recognizes the existence of these entities and attempts to delineate specific diagnostic criteria.作者: Afflict 時(shí)間: 2025-3-30 05:05
Chronic Myeloid Leukemia,ence has defined the molecular pathogenesis of chronic myeloid leukemia (CML) as unregulated signal transduction by the Bcr-Abl tyrosine kinase. Clinical studies have demonstrated that CML can be curable through immune-mediated elimination of leukemia cells by allogeneic T lymphocytes. Recently, spe
